VCAM-1-Functionalized Iron Oxide Nanoclusters for Targeted MRI-Based Diagnosis of Atherosclerosis

Abstract

This study explores the development and characterization of iron oxide nanoclusters (NCs) functionalized with vascular cell adhesion molecule 1 (VCAM-1) for targeted magnetic resonance imaging (MRI) of early atherosclerotic lesions. The NCs were synthesized via a high-temperature polyol method and functionalized using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide (EDC/NHS) chemistry to enable conjugation with VCAM-1 antibodies. Dynamic light scattering and transmission electron microscopy TEM confirmed controlled growth of NCs with a size ranging from 40 nm, in the parent to 110 nm post-functionalization, maintaining though colloidal stability in aqueous media. Cytotoxicity assays using mesenchymal stem cells (MSCs) demonstrated high biocompatibility. Confocal and electron microscopy confirmed specific binding of VCAM-1-NCs to VCAM-1-overexpressing MSCs under inflammatory conditions, with internalization through the endolysosomal pathway. The functionalized NCs remained bound under shear stress in an orbital flow model, mimicking early atherosclerotic conditions. MRI phantom analysis demonstrated preserved contrast capability despite increased T₂* relaxation times following antibody conjugation. These findings highlight the potential of VCAM-1-NCs as noninvasive imaging agents for early-stage atherosclerosis and vascular inflammation. Although this study is limited by the lack of in vivo validation and therapeutic evaluation, it provides a strong foundation for future translational research.

Keywords

diagnosis of atherosclerosis / iron oxide nanoclusters / MRI targeted contrast agents / multicore nanoparticles / theranostic nanoparticles / VCAM-1-functionalised vehicles

References

[1] W. Herrington, B. Lacey, P. Sherliker, J. Armitage, and S. Lewington, “Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease,” Circulation Research 118, no. 4 (2016): 535–546.

[2] D. Gao, Y. S. Cai, Y. Pan, Q. Ma, and W. Xie, “Editorial: Epidemiology and Clinical Researches in Atherosclerosis and Cardiovascular Disease,” Frontiers in Cardiovascular Medicine 10 (2023): 1212269.

[3] G. Casolo, J. Del Meglio, and C. Tessa, “Epidemiology and Pathophysiologic Insights of Coronary Atherosclerosis Relevant for Contemporary Non-Invasive Imaging,” Cardiovascular Diagnosis and Therapy 10, no. 6 (2020): 1906–1917.

[4] P. Libby and B. L. Ebert, “CHIP (Clonal Hematopoiesis of Indeterminate Potential): Potent and Newly Recognized Contributor to Cardiovascular Risk,” Circulation 138, no. 7 (2018): 666–668.

[5] K. J. Moore, S. Koplev, E. A. Fisher, et al., “Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis,” Journal of the American College of Cardiology 72, no. 18 (2018): 2181–2197.

[6] F. Abdolmaleki, S. M. Gheibi Hayat, V. Bianconi, T. P. Johnston, and A. Sahebkar, “Atherosclerosis and Immunity: A Perspective,” Trends in Cardiovascular Medicine 29, no. 6 (2019): 363–371.

[7] J. F. Bentzon, F. Otsuka, R. Virmani, and E. Falk, “Mechanisms of Plaque Formation and Rupture,” Circulation Research 114, no. 12 (2014): 1852–1866.

[8] J. Stewart, K. Addy, S. Campbell, and P. Wilkinson, “Primary Prevention of Cardiovascular Disease: Updated Review of Contemporary Guidance and Literature,” JRSM Cardiovascular Disease 9 (2020): 2048004020949326.

[9] M. Tavakol, S. Ashraf, and S. J. Brener, “Risks and Complications of Coronary Angiography: A Comprehensive Review,” Global Journal of Health Science 4, no. 1 (2012): 65–93.

[10] S. E. Nissen, “Limitations of Computed Tomography Coronary Angiography,” Journal of the American College of Cardiology 52, no. 25 (2008): 2145–2147.

[11] M. M. Michelsen, N. D. Mygind, D. Frestad, and E. Prescott, “Women With Stable Angina Pectoris and No Obstructive Coronary Artery Disease: Closer to a Diagnosis,” European Cardiology Review 12, no. 1 (2017): 14–19.

[12] A. Barioli and G. Tarantini, “Ischemia With Nonobstructive Coronary Artery Disease,” JACC: Asia 3, no. 4 (2023): 686.

[13] S. Z. Gu, M. E. Ahmed, Y. Huang, et al., “Comprehensive Biomechanical and Anatomical Atherosclerotic Plaque Metrics Predict Major Adverse Cardiovascular Events: A New Tool for Clinical Decision Making,” Atherosclerosis 390 (2024): 117449.

[14] A. M. Freeman, S. V. Raman, M. Aggarwal, et al., “Integrating Coronary Atherosclerosis Burden and Progression With Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making,” American Journal of Medicine 136, no. 3 (2023): 260–269.e7.

[15] V. I. Jurtz, G. Skovbjerg, C. G. Salinas, et al., “Deep Learning Reveals 3D Atherosclerotic Plaque Distribution and Composition,” Scientific Reports 10, no. 1 (2020): 21523.

[16] H. Meng, J. Ruan, Z. Yan, et al., “New Progress in Early Diagnosis of Atherosclerosis,” International Journal of Molecular Sciences 23, no. 16 (2022): 8939.

[17] A. Murgia, A. Balestrieri, P. Crivelli, et al., “Cardiac Computed Tomography Radiomics: An Emerging Tool for the Non-Invasive Assessment of Coronary Atherosclerosis,” Cardiovascular Diagnosis and Therapy 10, no. 6 (2020): 2005–2017.

[18] O. Terrada, B. Cherradi, A. Raihani, and O. Bouattane, “A Novel Medical Diagnosis Support System for Predicting Patients With Atherosclerosis Diseases,” Informatics in Medicine Unlocked 21 (2020): 100483.

[19] Ł. Artyszuk, E. Błażejowska, Z. Danielecka, J. Jurek, E. Olek, and P. Abramczyk, “Peripheral Atherosclerosis Evaluation Through Ultrasound: A Promising Diagnostic Tool for Coronary Artery Disease,” Echocardiography 40, no. 8 (2023): 841–851.

[20] Z. Zheng, D. Yuan, C. Shen, Z. Zhang, J. Ye, and L. Zhu, “Identification of Potential Diagnostic Biomarkers of Atherosclerosis Based on Bioinformatics Strategy,” BMC Medical Genomics 16, no. 1 (2023): 100.

[21] C. M. Kramer and J. D. Anderson, “MRI of Atherosclerosis: Diagnosis and Monitoring Therapy,” Expert Review of Cardiovascular Therapy 5, no. 1 (2007): 69–80.

[22] R. C. I. Wüst, C. Calcagno, M. R. R. Daal, A. J. Nederveen, B. F. Coolen, and G. J. Strijkers, “Emerging Magnetic Resonance Imaging Techniques for Atherosclerosis Imaging,” Arteriosclerosis, Thrombosis, and Vascular Biology 39, no. 5 (2019): 841–849.

[23] D. E. Sosnovik, M. Nahrendorf, and R. Weissleder, “Magnetic Nanoparticles for MR Imaging: Agents, Techniques and Cardiovascular Applications,” Basic Research in Cardiology 103, no. 2 (2008): 122–130.

[24] Y. D. Xiao, R. Paudel, J. Liu, C. Ma, Z. S. Zhang, and S. K. Zhou, “MRI Contrast Agents: Classification and Application (Review),” International Journal of Molecular Medicine 38, no. 5 (2016): 1319–1326.

[25] Y. X. J. Wang, “Current Status of Superparamagnetic Iron Oxide Contrast Agents for Liver Magnetic Resonance Imaging,” World Journal of Gastroenterology 21, no. 47 (2015): 13400–13402.

[26] H. Yue, J. A. Park, S. L. Ho, et al., “New Class of Efficient T(2) Magnetic Resonance Imaging Contrast Agent: Carbon-Coated Paramagnetic Dysprosium Oxide Nanoparticles,” Pharmaceuticals 13, no. 10 (2020): 312.

[27] P. Szomolanyi, M. Rohrer, T. Frenzel, et al., “Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T,” Investigative Radiology 54, no. 9 (2019): 559–564.

[28] E. Kuchma, P. Zolotukhin, A. Belanova, et al., “Low Toxic Maghemite Nanoparticles for Theranostic Applications,” International Journal of Nanomedicine 12 (2017): 6365–6371.

[29] J. Matuszak, B. Lutz, A. Sekita, et al., “Drug Delivery to Atherosclerotic Plaques Using Superparamagnetic Iron Oxide Nanoparticles,” International Journal of Nanomedicine 13 (2018): 8443–8460.

[30] H. Arami, A. Khandhar, D. Liggitt, and K. M. Krishnan, “In Vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles,” Chemical Society Reviews 44, no. 23 (2015): 8576–8607.

[31] Y. Chen and S. Hou, “Recent Progress in the Effect of Magnetic Iron Oxide Nanoparticles on Cells and Extracellular Vesicles,” Cell Death Discovery 9, no. 1 (2023): 195.

[32] M. A. Bruckman, K. Jiang, E. J. Simpson, et al., “Dual-Modal Magnetic Resonance and Fluorescence Imaging of Atherosclerotic Plaques In Vivo Using VCAM-1 Targeted Tobacco Mosaic Virus,” Nano Letters 14, no. 3 (2014): 1551–1558.

[33] M. I. Cybulsky, K. Iiyama, H. Li, et al., “A Major Role for VCAM-1, but Not ICAM-1, in Early Atherosclerosis,” Journal of Clinical Investigation 107, no. 10 (2001): 1255–1262.

[34] W. Mu, M. Chen, Z. Gong, F. Zheng, and Q. Xing, “Expression of Vascular Cell Adhesion molecule-1 in the Aortic Tissues of Atherosclerotic Patients and the Associated Clinical Implications,” Experimental and Therapeutic Medicine 10, no. 2 (2015): 423–428.

[35] A. Broisat, S. Hernot, J. Toczek, et al., “Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions,” Circulation Research 110, no. 7 (2012): 927–937.

[36] A. Broisat, J. Toczek, L. S. Dumas, et al., “99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice,” Journal of Nuclear Medicine 55, no. 10 (2014): 1678–1684.

[37] K. A. Kelly, J. R. Allport, A. Tsourkas, V. R. Shinde-Patil, L. Josephson, and R. Weissleder, “Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle,” Circulation Research 96, no. 3 (2005): 327–336.

[38] M. Nahrendorf, F. A. Jaffer, K. A. Kelly, et al., “Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis,” Circulation 114, no. 14 (2006): 1504–1511.

[39] A. Tsourkas, V. R. Shinde-Patil, K. A. Kelly, et al., “In Vivo Imaging of Activated Endothelium Using an Anti-VCAM-1 Magnetooptical Probe,” Bioconjugate Chemistry 16, no. 3 (2005): 576–581.

[40] A. Kostopoulou, K. Brintakis, M. Vasilakaki, et al., “Assembly-Mediated Interplay of Dipolar Interactions and Surface Spin Disorder in Colloidal Maghemite Nanoclusters,” Nanoscale 6, no. 7 (2014): 3764–3776.

[41] A. Kostopoulou, K. Brintakis, E. Fragogeorgi, et al., “Iron Oxide Colloidal Nanoclusters as Theranostic Vehicles and Their Interactions at the Cellular Level,” Nanomaterials 8, no. 5 (2018): 315.

[42] M. J. Fischer, “Amine Coupling Through EDC/NHS: A Practical Approach,” Methods in Molecular Biology 627 (2010): 55–73.

[43] S. Asiaei, B. Smith, and P. Nieva, “Enhancing Contact Interface for Biomolecule Immobilization Using a Microfluidic-Assisted QCM Sensor,” Biosensors and Bioelectronics 117 (2018): 623–629.

[44] J. H. Ko and H. D. Maynard, “A Guide to Maximizing the Therapeutic Potential of Protein-Polymer Conjugates by Rational Design,” Chemical Society Reviews 47, no. 24 (2018): 8998–9014.

[45] Y. X. J. Wáng and J. M. Idée, “A Comprehensive Literatures Update of Clinical Researches of Superparamagnetic Resonance Iron Oxide Nanoparticles for Magnetic Resonance Imaging,” Quantitative Imaging in Medicine and Surgery 7, no. 1 (2017): 88–122.

[46] Y. X. Wang, “Superparamagnetic Iron Oxide Based MRI Contrast Agents: Current Status of Clinical Application,” Quantitative Imaging in Medicine and Surgery 1, no. 1 (2011): 35–40.

[47] Y. X. J. Wang, S. M. Hussain, and G. P. Krestin, “Superparamagnetic Iron Oxide Contrast Agents: Physicochemical Characteristics and Applications in MR Imaging,” European Radiology 11, no. 11 (2001): 2319–2331.

[48] S. Belicky, P. Damborsky, J. Zapatero-Rodríguez, R. O'Kennedy, and J. Tkac, “Full-Length Antibodies Versus Single-Chain Antibody Fragments for a Selective Impedimetric Lectin-Based Glycoprofiling of Prostate Specific Antigen,” Electrochimica Acta 246 (2017): 399–405.

[49] V. Crivianu-Gaita and M. Thompson, “Aptamers, Antibody Scfv, and Antibody Fab’ Fragments: An Overview and Comparison of Three of the Most Versatile Biosensor Biorecognition Elements,” Biosensors and Bioelectronics 85 (2016): 32–45.

[50] Y. Chenyakin, D. A. Ullmann, E. Evoy, L. Renbaum-Wolff, S. Kamal, and A. K. Bertram, “Diffusion Coefficients of Organic Molecules in Sucrose–Water Solutions and Comparison With Stokes–Einstein Predictions,” Atmospheric Chemistry and Physics 17, no. 3 (2017): 2423–2435.

[51] P. Bihari, M. Vippola, S. Schultes, et al., “Optimized Dispersion of Nanoparticles for Biological In Vitro and In Vivo Studies,” Particle and Fibre Toxicology 5 (2008): 14.

[52] T. Nissinen, S. Näkki, H. Laakso, et al., “Tailored Dual PEGylation of Inorganic Porous Nanocarriers for Extremely Long Blood Circulation In Vivo,” ACS Applied Materials & Interfaces 8, no. 48 (2016): 32723–32731.

[53] M. A. Wells, A. Abid, I. M. Kennedy, and A. I. Barakat, “Serum Proteins Prevent Aggregation of Fe₂O₃ and ZnO Nanoparticles,” Nanotoxicology 6 (2012): 837–846.

[54] C. Schweiger, R. Hartmann, F. Zhang, W. J. Parak, T. H. Kissel, and P. Rivera_Gil, “Quantification of the Internalization Patterns of Superparamagnetic Iron Oxide Nanoparticles With Opposite Charge,” Journal of Nanobiotechnology 10 (2012): 28.

[55] N. Lee, D. Yoo, D. Ling, M. H. Cho, T. Hyeon, and J. Cheon, “Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive Therapy,” Chemical Reviews 115, no. 19 (2015): 10637–10689.

[56] R. N. Muller, “ Contrast Agents in Whole Body Magnetic Resonance: Operating Mechanisms.” Encyclopedia of Nuclear Magnetic Resonance (Wiley J. and Sons, 1996).

[57] Z. Zhou, L. Yang, J. Gao, and X. Chen, “Structure-Relaxivity Relationships of Magnetic Nanoparticles for Magnetic Resonance Imaging,” Advanced Materials 31, no. 8 (2019): e1804567.

[58] Q. L. Vuong, J. F. Berret, J. Fresnais, Y. Gossuin, and O. Sandre, “A Universal Scaling Law to Predict the Efficiency of Magnetic Nanoparticles as MRI T2 Contrast Agents,” Advanced Healthcare Materials 1, no. 4 (2012): 502–512.

[59] D. Yoo, J. H. Lee, T. H. Shin, and J. Cheon, “Theranostic Magnetic Nanoparticles,” Accounts of Chemical Research 44, no. 10 (2011): 863–874.

[60] C. Blanco-Andujar, A. Walter, G. Cotin, et al., “Design of Iron Oxide-Based Nanoparticles for MRI and Magnetic Hyperthermia,” Nanomedicine 11, no. 14 (2016): 1889–1910.

[61] A. Kostopoulou, S. K. P. Velu, K. Thangavel, et al., “Colloidal Assemblies of Oriented Maghemite Nanocrystals and Their NMR Relaxometric Properties,” Dalton Transactions 43, no. 22 (2014): 8395–8404.

[62] A. H. Haghighi, M. T. Khorasani, Z. Faghih, and F. Farjadian, “Effects of Different Quantities of Antibody Conjugated With Magnetic Nanoparticles on Cell Separation Efficiency,” Heliyon 6, no. 4 (2020): e03677.

[63] Z. Li, J. Zhang, X. Guo, X. Guo, and Z. Zhang, “Multi-Functional Magnetic Nanoparticles as an Effective Drug Carrier for the Controlled Anti-Tumor Treatment,” Journal of Biomaterials Applications 32, no. 2 (2018): 967–976.

[64] J. F. Liu, B. Jang, D. Issadore, and A. Tsourkas, “Use of Magnetic Fields and Nanoparticles to Trigger Drug Release and Improve Tumor Targeting,” WIREs Nanomedicine and Nanobiotechnology 11, no. 6 (2019): e1571.

[65] B. Garcia-Pinel, A. Ortega-Rodríguez, C. Porras-Alcalá, et al., “Magnetically Active pNIPAM Nanosystems as Temperature-Sensitive Biocompatible Structures for Controlled Drug Delivery,” Artificial Cells, Nanomedicine, and Biotechnology 48, no. 1 (2020): 1022–1035.

[66] M. Vassallo, D. Martella, G. Barrera, et al., “Improvement of Hyperthermia Properties of Iron Oxide Nanoparticles by Surface Coating,” ACS Omega 8, no. 2 (2023): 2143–2154.

[67] N. G. Welch, J. A. Scoble, B. W. Muir, and P. J. Pigram, “Orientation and Characterization of Immobilized Antibodies for Improved Immunoassays (Review),” Biointerphases 12, no. 2 (2017): 02D301.

[68] M. Fuentes, C. Mateo, J. M. Guisán, and R. Fernández-Lafuente, “Preparation of Inert Magnetic Nano-Particles for the Directed Immobilization of Antibodies,” Biosensors and Bioelectronics 20, no. 7 (2005): 1380–1387.

[69] M. A. Bruckman, K. Jiang, E. J. Simpson, et al., “Dual-Modal Magnetic Resonance and Fluorescence Imaging of Atherosclerotic Plaques In Vivo Using VCAM-1 Targeted Tobacco Mosaic Virus,” Nano Letters 14, no. 3 (2014): 1551–1558.

[70] C. Burtea, S. Ballet, S. Laurent, et al., “Development of a Magnetic Resonance Imaging Protocol for the Characterization of Atherosclerotic Plaque by Using Vascular Cell Adhesion Molecule-1 and Apoptosis-Targeted Ultrasmall Superparamagnetic Iron Oxide Derivatives,” Arteriosclerosis, Thrombosis, and Vascular Biology 32, no. 6 (2012): e36–e48.

[71] F. Yan, W. Yang, X. Li, et al., “Magnetic Resonance Imaging of Atherosclerosis Using CD81-Targeted Microparticles of Iron Oxide in Mice,” BioMed Research International 2015 (2015): 758616.

[72] S. Wen, D. F. Liu, Y. Cui, et al., “In Vivo MRI Detection of Carotid Atherosclerotic Lesions and Kidney Inflammation in ApoE-Deficient Mice by Using LOX-1 Targeted Iron Nanoparticles,” Nanomedicine: Nanotechnology, Biology and Medicine 10, no. 3 (2014): 639–649.

[73] N. Lee, D. Yoo, D. Ling, M. H. Cho, T. Hyeon, and J. Cheon, “Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive Therapy,” Chemical Reviews 115, no. 19 (2015): 10637–10689.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).